These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36129280)

  • 1. Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.
    Mossoff A; Adalja A
    Inquiry; 2022; 59():469580221124819. PubMed ID: 36129280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.
    Ballano VO
    Linacre Q; 2022 Feb; 89(1):47-63. PubMed ID: 35321490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intellectual Property and the Politics of Public Good during COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.
    Fischer SE; Vitale L; Agutu AL; Kavanagh MM
    J Health Polit Policy Law; 2024 Feb; 49(1):9-42. PubMed ID: 37522338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
    Chattu VK; Singh B; Kaur J; Jakovljevic M
    Biomed Res Int; 2021; 2021():6658070. PubMed ID: 34485525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pandemics, intellectual property and 'our economy': A worldview analysis of Canada's role in compromising global access to COVID-19 vaccines.
    Brisbois B; Plamondon K; Walugembe D; Pereira RC; Edet C; Dixon J; Habibi R; Karamouzian M; Labonté R; Murthy S; Ravitsky V
    Glob Public Health; 2024 Jan; 19(1):2335360. PubMed ID: 38626321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.
    Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Kana BD; Arbuthnot P; Botwe BK; Choonara YE; Hassan F; Louzir H; Matsoso P; Moore PL; Muhairwe A; Naidoo K; Ndomondo-Sigonda M; Madhi SA
    Lancet Infect Dis; 2023 Aug; 23(8):e288-e300. PubMed ID: 37290473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The COVID-19 Pandemic and the TRIPS Waiver: Patents and Flexibility.
    Lawson C; Rourke M
    J Law Med; 2022 Aug; 29(3):663-676. PubMed ID: 36056658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Intellectual Property the COVID-19 Bad Guy? Lessons We Could Learn from the Pandemic.
    Lawson C
    J Law Med; 2023 Dec; 30(3):538-554. PubMed ID: 38332594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intellectual Property Rights and Vaccines.
    Gilbert P; Fawcett R; Coles J; Hillson W
    Methods Mol Biol; 2022; 2412():505-518. PubMed ID: 34918265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Economic Theory of Patent Protection and Pandemic Influenza Vaccines: Do Patents Really Incentivize Innovation in the Field?
    Eccleston-Turner M
    Am J Law Med; 2016 May; 42(2-3):572-597. PubMed ID: 29086638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIPS waiver of COVID-19 vaccines: Impact on pharmaceutical industry and what it means to developing countries.
    Chaudhary T; Chaudhary A
    J World Intellect Prop; 2021 Nov; 24(5-6):447-454. PubMed ID: 34908905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to COVID-19 Vaccines: A New Global Approach.
    Bouderhem R
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canada and the pharmaceutical industry in the time of COVID-19.
    Lexchin J
    Int J Soc Determinants Health Health Serv; 2023 Oct; 53(4):508-517. PubMed ID: 37574784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.